• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

获得性血友病A复发的预后因素——一项长期观察性研究的结果

Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study.

作者信息

Reich Lisa, Gatzke Florian, Rauchfuss Steffen, Roth Stefanie, Miesbach Wolfgang

机构信息

Medical Clinic 2, University Hospital Frankfurt, Germany.

出版信息

Res Pract Thromb Haemost. 2025 Feb 27;9(2):102707. doi: 10.1016/j.rpth.2025.102707. eCollection 2025 Feb.

DOI:10.1016/j.rpth.2025.102707
PMID:40177223
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11964528/
Abstract

OBJECTIVES

Acquired hemophilia A (AHA) is a rare autoimmune disease caused by autoantibodies against factor (F)VIII (FVIII), potentially leading to life-threatening bleeding. While predictors for remission have been analyzed, data on recurrence is lacking.

METHODS

This study investigated predictors of AHA recurrence in 41 patients. Patients were divided into 2 groups: those with recurrence ( = 18) and those in stable long-term remission ( = 23) with at least 1 year of follow-up.

RESULTS

All relapses occurred within 1 year of initial remission. The median follow-up period was 3.8 years (IQR, 1.8-6.4) for all included patients. Multivariate Cox regression analysis revealed that initial FVIII activity <1 IU/dL and failure to achieve initial complete remission (CR) were significant predictors of relapse. Kaplan-Meier curves showed significantly different relapse-free survival rates for patients with initial FVIII activity <1 IU/dL vs ≥1 IU/dL (χ[1] = 5.950,  = .015), and for those achieving initial CR vs partial remission (χ[1] = 6.570,  = .010).Other factors such as inhibitor titer, gender, age, World Health Organization scale, underlying disorder, controlled disorder, initial immunosuppressive therapy, immunosuppressive therapy escalation, and partial remission at day 21 showed no significant relation to recurrences. Overall survival did not differ significantly between relapsing and nonrelapsing patients (χ[1] = .896,  = .344).

CONCLUSION

Initial FVIII <1 IU/dL and failure to achieve initial CR are identified as risk factors for recurrence in AHA. Patients with these characteristics should be closely monitored for at least 1 year after initial remission due to increased recurrence risk.

摘要

目的

获得性血友病A(AHA)是一种由抗凝血因子(F)VIII(FVIII)自身抗体引起的罕见自身免疫性疾病,可能导致危及生命的出血。虽然已经分析了缓解的预测因素,但缺乏关于复发的数据。

方法

本研究调查了41例AHA患者复发的预测因素。患者分为两组:复发组(n = 18)和稳定长期缓解组(n = 23),随访至少1年。

结果

所有复发均发生在初次缓解后的1年内。所有纳入患者的中位随访期为3.8年(四分位间距,1.8 - 6.4)。多因素Cox回归分析显示,初始FVIII活性<1 IU/dL和未实现初次完全缓解(CR)是复发的重要预测因素。Kaplan-Meier曲线显示,初始FVIII活性<1 IU/dL与≥1 IU/dL的患者无复发生存率有显著差异(χ[1]=5.950,P = 0.015),实现初次CR与部分缓解的患者无复发生存率有显著差异(χ[1]=6.570,P = 0.010)。其他因素,如抑制物滴度、性别、年龄、世界卫生组织分级、基础疾病、可控疾病、初始免疫抑制治疗、免疫抑制治疗升级以及第21天的部分缓解与复发无显著关系。复发患者和未复发患者的总生存率无显著差异(χ[1]=0.896,P = 0.344)。

结论

初始FVIII<1 IU/dL和未实现初次CR被确定为AHA复发的危险因素。由于复发风险增加,具有这些特征的患者在初次缓解后应密切监测至少1年。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/34d47b779db7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/ee36f968afb9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/4902ea6ad0b8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/e657e5845cc5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/34d47b779db7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/ee36f968afb9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/4902ea6ad0b8/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/e657e5845cc5/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eba8/11964528/34d47b779db7/gr4.jpg

相似文献

1
Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study.获得性血友病A复发的预后因素——一项长期观察性研究的结果
Res Pract Thromb Haemost. 2025 Feb 27;9(2):102707. doi: 10.1016/j.rpth.2025.102707. eCollection 2025 Feb.
2
Relapse pattern and long-term outcomes in subjects with acquired haemophilia A.获得性血友病 A 患者的复发模式和长期结局。
Haemophilia. 2019 Mar;25(2):252-257. doi: 10.1111/hae.13685. Epub 2019 Jan 29.
3
Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.获得性血友病A(AHA)缓解及生存的预后因素:GTH-AH 01/2010研究结果
Blood. 2015 Feb 12;125(7):1091-7. doi: 10.1182/blood-2014-07-587089. Epub 2014 Dec 18.
4
Overshoot of FVIII activity in patients with acquired hemophilia A who achieve complete remission.获得性血友病 A 患者达到完全缓解时的 FVIII 活性过度。
Int J Hematol. 2020 Apr;111(4):544-549. doi: 10.1007/s12185-020-02823-y. Epub 2020 Jan 14.
5
The factor VIII:C/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study.VIII:C/VWF:Ag 比值作为预测获得性血友病 A 患者复发的有用工具:一项回顾性队列研究。
Haemophilia. 2019 May;25(3):527-534. doi: 10.1111/hae.13752. Epub 2019 May 2.
6
Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort.识别获得性血友病 A 患者的风险因素和优化护理标准:来自捷克患者队列的结果。
Haemophilia. 2020 Jul;26(4):643-651. doi: 10.1111/hae.14084. Epub 2020 Jun 26.
7
Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: A retrospective single-center study.八因子水平及其抑制剂滴度对获得性血友病单纯使用皮质类固醇治疗反应的影响:一项回顾性单中心研究
Medicine (Baltimore). 2016 Nov;95(48):e5232. doi: 10.1097/MD.0000000000005232.
8
Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.类风湿关节炎患者获得性血友病:病例报告
Blood Coagul Fibrinolysis. 2013 Dec;24(8):874-80. doi: 10.1097/MBC.0b013e3283646635.
9
Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.获得性血友病 A 中因子 VIII 结合抗体的诊断和预后价值:来自 GTH-AH 01/2010 研究的数据。
J Thromb Haemost. 2016 May;14(5):940-7. doi: 10.1111/jth.13304. Epub 2016 Apr 22.
10
Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.十二年获得性血友病 A 诊治经验:南澳大利亚的曲折历程。
Semin Thromb Hemost. 2009 Nov;35(8):769-77. doi: 10.1055/s-0029-1245109. Epub 2010 Feb 18.

本文引用的文献

1
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.环磷酰胺与利妥昔单抗治疗获得性血友病 A 患者抑制物:108 例患者的随机试验。
Thromb Res. 2024 May;237:79-87. doi: 10.1016/j.thromres.2024.03.012. Epub 2024 Mar 15.
2
Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.艾美赛珠单抗治疗获得性血友病A:GTH - AHA工作组的共识建议
Hamostaseologie. 2024 Dec;44(6):466-471. doi: 10.1055/a-2197-9738. Epub 2023 Dec 4.
3
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
依库珠单抗预防获得性血友病 A 患者出血(GTH-AHA-EMI):一项开放标签、单臂、多中心、2 期研究。
Lancet Haematol. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6. Epub 2023 Oct 16.
4
Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen.联合免疫抑制治疗获得性血友病 A:CyDRi 是一种高效低毒的方案。
Blood. 2022 Nov 3;140(18):1983-1992. doi: 10.1182/blood.2022016873.
5
Time is Blood: The Impact of Diagnostic Delays on Acquired Hemophilia A.时间就是血液:诊断延迟对获得性血友病A的影响。
Cureus. 2022 Feb 9;14(2):e22048. doi: 10.7759/cureus.22048. eCollection 2022 Feb.
6
Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: A systematic literature review.产后获得性血友病 A 及其在后续妊娠中复发的风险:系统文献综述。
Haemophilia. 2021 Mar;27(2):199-210. doi: 10.1111/hae.14233. Epub 2021 Feb 6.
7
Should emicizumab be used in patients with acquired hemophilia A?获得性血友病A患者是否应使用艾美赛珠单抗?
J Thromb Haemost. 2021 Mar;19(3):637-644. doi: 10.1111/jth.15208.
8
Emicizumab for the treatment of acquired hemophilia A.依库珠单抗治疗获得性血友病 A。
Blood. 2021 Jan 21;137(3):410-419. doi: 10.1182/blood.2020006315.
9
Identifying risk factors and optimizing standard of care for patients with acquired haemophilia A: Results from a Czech patient cohort.识别获得性血友病 A 患者的风险因素和优化护理标准:来自捷克患者队列的结果。
Haemophilia. 2020 Jul;26(4):643-651. doi: 10.1111/hae.14084. Epub 2020 Jun 26.
10
International recommendations on the diagnosis and treatment of acquired hemophilia A.国际上关于获得性血友病 A 的诊断和治疗建议。
Haematologica. 2020 Jul;105(7):1791-1801. doi: 10.3324/haematol.2019.230771. Epub 2020 May 7.